Tag: cases

At the initiative and by the decision of the Board of AUGA group, RAB (code 126264360, address Konstitucijos ave. 21C, Vilnius, the “Company”), it has been decided to revoke the extraordinary General Meeting of Shareholders convened on July 14, 2025, following the decision of the Vilnius Regional Court to extend the deadline for submitting the Company's restructuring plan for Court approval until August 19, 2025. This Court decision was based on unresolved issues regarding the contested creditor claims in the Company's restructuring case, which currently prevent the creditors from making decisions in accordance with the Law on Legal Entities' Insolvency (hereinafter referred to as the "Insolvency Law").

Discover why the Matsato Knife is gaining global recognition in 2025. Explore expert insights, key features, and authentic user experiences behind this precision-crafted Japanese blade.

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, all dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI’s top executives with violations of the Securities Exchange Act of 1934.

NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.

NEW YORK and NEW ORLEANS, July 01, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

NEW YORK and NEW ORLEANS, July 01, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 4, 2025 to file lead plaintiff applications in a securities class action lawsuit against Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) (OTC: RBGLY), if they purchased the Company’s American Depositary Shares (“ADSs”) between January 13, 2021 and July 28, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.